Junli Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Junli Zhang has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
- Kaixiang Zhang
Zhengzhou University
7 shared publications Hua Gao
Department of Pathogen Biology, School of Basic Medical Sciences
6 shared publicationsHongling Zhang
Zhengzhou University
5 shared publicationsMin Lv
Zhengzhou Univ, Sch Pharmaceut Sci, Zhengzhou 450001, Peoples R China
5 shared publicationsZhenzhong Zhang
Zhengzhou Univ, Sch Pharmaceut Sci, Zhengzhou 450001, Peoples R China
5 shared publicationsDi Huang
4 shared publications
Latest Publications
- 22 July 2026
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 18 (30) , 40596-40611
Anti-Infection and Immunoregulatory Multifunctional Hydrogel for Synergistic Treatment of Diabetic Wounds
Effective healing of diabetic wounds requires comprehensive management of bacterial infection, modulation of excessive inflammation, and promotion of cellular proliferation. Current clinical strategies include systemic blood glucose control combined with localized interventions such as debridement, antibiotic regimens, and advanced wound dressings. However, the efficacy of these strategies is often limited by challenges like antibiotic resistance. To overcome these challenges, we developed an anti-infection and immunoregulatory hydrogel loaded with two bioactive nanopreparations derived from Houttuynia cordata Thunb. (H. cordata). The one component, comprising carbon dots (CDs) synthesized via hydrothermal method using H. cordata and then modified with polyethylenimine (PEI) to form PEI-modified CDs (PCDs), demonstrates potent antibacterial activity. The other consists of plant-derived extracellular vesicles (EVs) that exhibit strong antioxidative and anti-inflammatory properties, effectively reducing reactive oxygen species levels, attenuating inflammatory responses, and promoting fibroblast proliferation and migration. These two components were co-incorporated into methylacrylated gelatin (GelMA) to form composite termed Gel@P&E. This system enables the sustained release of both PCDs and EVs, thereby coordinately regulating inflammation and facilitating tissue regeneration. In summary, this study successfully constructs multifunctional hydrogel platform that integrates anti-infective and immunoregulatory functions, presenting an alternative therapeutic strategy for diabetic wounds management.
- 22 July 2026
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 18 (30) , 40596-40611
Anti-Infection and Immunoregulatory Multifunctional Hydrogel for Synergistic Treatment of Diabetic Wounds
Effective healing of diabetic wounds requires comprehensive management of bacterial infection, modulation of excessive inflammation, and promotion of cellular proliferation. Current clinical strategies include systemic blood glucose control combined with localized interventions such as debridement, antibiotic regimens, and advanced wound dressings. However, the efficacy of these strategies is often limited by challenges like antibiotic resistance. To overcome these challenges, we developed an anti-infection and immunoregulatory hydrogel loaded with two bioactive nanopreparations derived from Houttuynia cordata Thunb. (H. cordata). The one component, comprising carbon dots (CDs) synthesized via hydrothermal method using H. cordata and then modified with polyethylenimine (PEI) to form PEI-modified CDs (PCDs), demonstrates potent antibacterial activity. The other consists of plant-derived extracellular vesicles (EVs) that exhibit strong antioxidative and anti-inflammatory properties, effectively reducing reactive oxygen species levels, attenuating inflammatory responses, and promoting fibroblast proliferation and migration. These two components were co-incorporated into methylacrylated gelatin (GelMA) to form composite termed Gel@P&E. This system enables the sustained release of both PCDs and EVs, thereby coordinately regulating inflammation and facilitating tissue regeneration. In summary, this study successfully constructs multifunctional hydrogel platform that integrates anti-infective and immunoregulatory functions, presenting an alternative therapeutic strategy for diabetic wounds management.
- 26 September 2025
- Published by American Chemical Society (ACS) in ACS Sensors
- Vol. 10 (10) , 7291-7301
Early Diagnosis of Kidney Injury via Ultrasensitive Detection of Urine-Derived Exosomes Using a Dual-Signal Amplification Strategy
Kidney injury is one of the most serious health problems, including drug-induced acute kidney injury (AKI) and disease-induced chronic kidney disease. Neutrophil gelatinase-associated lipocalin (NGAL) carried by urinary exosomes (uExos) has emerged as a potential biomarker for the diagnosis of kidney injury. However, sensitive detection of urinary exosomal NGAL remains challenging due to its low abundance in urine during the early stages of kidney injury. In this study, we developed a highly sensitive uExos analysis platform by integrating deoxyribonuclease I (DNase I)-mediated biomarker cycling with a metal-enhanced fluorescence (MEF) effect for dual fluorescence signal amplification. This method achieved a remarkably low limit of detection (LOD) of 3.02 × 103 particles/mL, with a linear range from 5 × 103 to 2 × 1011 particles/mL. Using this approach, we successfully distinguished urine samples from diabetic nephropathy (DN) patients and healthy donors (HD) by analyzing the level of urinary exosomal NGAL. Moreover, in a rat model of cisplatin-induced AKI, our strategy detected abnormalities as early as 12 h postcisplatin injection─significantly earlier than conventional clinical biomarkers such as serum creatinine (sCr) and blood urea nitrogen (BUN). Additionally, this method demonstrated the potential for accurately evaluating the efficacy of anti-AKI therapeutics. In summary, the dual signal amplification strategy presented in this study facilitates early diagnosis of both chronic and acute kidney injury while offering a powerful tool for dynamically monitoring therapeutic responses in kidney disease.
- 26 September 2025
- Published by American Chemical Society (ACS) in ACS Sensors
- Vol. 10 (10) , 7291-7301
Early Diagnosis of Kidney Injury via Ultrasensitive Detection of Urine-Derived Exosomes Using a Dual-Signal Amplification Strategy
Kidney injury is one of the most serious health problems, including drug-induced acute kidney injury (AKI) and disease-induced chronic kidney disease. Neutrophil gelatinase-associated lipocalin (NGAL) carried by urinary exosomes (uExos) has emerged as a potential biomarker for the diagnosis of kidney injury. However, sensitive detection of urinary exosomal NGAL remains challenging due to its low abundance in urine during the early stages of kidney injury. In this study, we developed a highly sensitive uExos analysis platform by integrating deoxyribonuclease I (DNase I)-mediated biomarker cycling with a metal-enhanced fluorescence (MEF) effect for dual fluorescence signal amplification. This method achieved a remarkably low limit of detection (LOD) of 3.02 × 103 particles/mL, with a linear range from 5 × 103 to 2 × 1011 particles/mL. Using this approach, we successfully distinguished urine samples from diabetic nephropathy (DN) patients and healthy donors (HD) by analyzing the level of urinary exosomal NGAL. Moreover, in a rat model of cisplatin-induced AKI, our strategy detected abnormalities as early as 12 h postcisplatin injection─significantly earlier than conventional clinical biomarkers such as serum creatinine (sCr) and blood urea nitrogen (BUN). Additionally, this method demonstrated the potential for accurately evaluating the efficacy of anti-AKI therapeutics. In summary, the dual signal amplification strategy presented in this study facilitates early diagnosis of both chronic and acute kidney injury while offering a powerful tool for dynamically monitoring therapeutic responses in kidney disease.
- 14 April 2025
- Published by American Chemical Society (ACS) in ACS Biomaterials Science & Engineering
- Vol. 11 (5) , 2653-2663
Screening Isodon rubescens-Derived Vesicles Harvested at Different Periods as Carriers for the Treatment of Colitis-Associated Cancer
Plant-derived extracellular vesicles are of great significance in practical applications due to their availability, low immunogenicity, and effective carrier performance. Isodon rubescens-derived vesicles (IRDVs) not only have the capability for drug-carrying targeted therapy but also exhibit certain anti-inflammatory and antitumor effects as part of traditional Chinese medicine. The harvest time is closely related to the quality of its medicinal ingredients; however, whether there are differences in the IRDVs harvested at different times has yet to be explored. Herein, we analyzed the morphology and chemical composition of IRDVs collected at different time points and identified six-month-harvested IRDVs as the most suitable delivery vector. To further enhance their therapeutic potential, we modified the IRDVs with deoxycholic acid to facilitate the oral delivery of the chemotherapy drug doxorubicin (DOX). This novel nanotherapy, termed DOX-IRDVs@DA, was developed as an oral targeted treatment for colitis-associated cancer (CAC). The results demonstrated that DOX-IRDVs@DA effectively delivered DOX to colon tumor 26 (CT26) cells, induced cancer cell apoptosis by modulating apoptosis-related proteins, and inhibited the proliferation of CT26 cells. In vivo studies in a mouse model of CAC revealed that DOX-IRDVs@DA achieved superior targeted therapeutic effects, reducing the number of colonic nodules, restoring the structural integrity of the colon, and causing minimal systemic toxicity.
- 14 April 2025
- Published by American Chemical Society (ACS) in ACS Biomaterials Science & Engineering
- Vol. 11 (5) , 2653-2663
Screening Isodon rubescens-Derived Vesicles Harvested at Different Periods as Carriers for the Treatment of Colitis-Associated Cancer
Plant-derived extracellular vesicles are of great significance in practical applications due to their availability, low immunogenicity, and effective carrier performance. Isodon rubescens-derived vesicles (IRDVs) not only have the capability for drug-carrying targeted therapy but also exhibit certain anti-inflammatory and antitumor effects as part of traditional Chinese medicine. The harvest time is closely related to the quality of its medicinal ingredients; however, whether there are differences in the IRDVs harvested at different times has yet to be explored. Herein, we analyzed the morphology and chemical composition of IRDVs collected at different time points and identified six-month-harvested IRDVs as the most suitable delivery vector. To further enhance their therapeutic potential, we modified the IRDVs with deoxycholic acid to facilitate the oral delivery of the chemotherapy drug doxorubicin (DOX). This novel nanotherapy, termed DOX-IRDVs@DA, was developed as an oral targeted treatment for colitis-associated cancer (CAC). The results demonstrated that DOX-IRDVs@DA effectively delivered DOX to colon tumor 26 (CT26) cells, induced cancer cell apoptosis by modulating apoptosis-related proteins, and inhibited the proliferation of CT26 cells. In vivo studies in a mouse model of CAC revealed that DOX-IRDVs@DA achieved superior targeted therapeutic effects, reducing the number of colonic nodules, restoring the structural integrity of the colon, and causing minimal systemic toxicity.
- 16 October 2024
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 96 (43) , 17362-17369
Quantitative Analysis of Cell-Free RNA at Attomolar Level Using CRISPR/Cas Digital Imaging Platform
Quantitative analysis of cell-free RNA (cfRNA) in plasma sample can be used for screening, diagnosing, and prognosticating of multiple diseases. Here, we report a quantitative CRISPR/Cas digital imaging platform (qCasdip) for the detection of various cfRNAs, including circular RNAs and miRNAs, in clinical samples at the attomolar (aM) level without the need for preamplification. Digital counting strategy provides qCasdip quantitative ability with a linear detection range of 102-106 aM. Meanwhile, qCasdip demonstrated cfRNA profiling in clinical plasma samples, improving the diagnosis of breast cancer. These data highlight the potential of qCasdip to quantitatively assess the molecular patterns of specific cfRNA panels in plasma, thereby providing a novel liquid biopsy solution to enhance disease diagnosis.
- 16 October 2024
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 96 (43) , 17362-17369
Quantitative Analysis of Cell-Free RNA at Attomolar Level Using CRISPR/Cas Digital Imaging Platform
Quantitative analysis of cell-free RNA (cfRNA) in plasma sample can be used for screening, diagnosing, and prognosticating of multiple diseases. Here, we report a quantitative CRISPR/Cas digital imaging platform (qCasdip) for the detection of various cfRNAs, including circular RNAs and miRNAs, in clinical samples at the attomolar (aM) level without the need for preamplification. Digital counting strategy provides qCasdip quantitative ability with a linear detection range of 102-106 aM. Meanwhile, qCasdip demonstrated cfRNA profiling in clinical plasma samples, improving the diagnosis of breast cancer. These data highlight the potential of qCasdip to quantitatively assess the molecular patterns of specific cfRNA panels in plasma, thereby providing a novel liquid biopsy solution to enhance disease diagnosis.
- 22 May 2024
- Published by Elsevier in Analytica Chimica Acta
- Vol. 1314, 342779
Accurate and highly sensitive detection of Alzheimer's disease-related extracellular vesicles via förster resonance energy transfer
- 22 May 2024
- Published by Elsevier in Analytica Chimica Acta
- Vol. 1314, 342779
Accurate and highly sensitive detection of Alzheimer's disease-related extracellular vesicles via förster resonance energy transfer
- 25 October 2023
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 95 (44) , 16433
Correction to “CasSABER for Programmable In Situ Visualization of Low and Nonrepetitive Gene Loci”
- 25 October 2023
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 95 (44) , 16433
Correction to “CasSABER for Programmable In Situ Visualization of Low and Nonrepetitive Gene Loci”
- 11 October 2023
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 17 (20) , 20120-20134
Localized Imaging of Programmed Death-Ligand 1 on Individual Tumor-Derived Extracellular Vesicles for Prediction of Immunotherapy Response
Programmed death-ligand 1 (PD-L1) on tumor-derived small extracellular vesicles (EVs) is a biomarker for prediction of the immunotherapy response. However, conventional bulk measurement can hardly analyze the expression of PD-L1 on individual tumor-derived EVs. Herein, a method for localized imaging of tumor-derived individual EVs PD-L1 (LITIE) is developed. In this assay, EVs in plasma were directly captured on a biochip. Then the liposome-mediated membrane fusion strategy was used to image miR-21 in EVs to discriminate miR-21-positive EVs from the whole EVs populations. Subsequently, the primer exchange reaction (PER) is applied to generate localized and amplified fluorescent signals for imaging PD-L1 on identified tumor-derived EVs. When applied in clinical sample tests, the LITIE assay could effectively distinguish breast cancer patients from healthy donors or patients with benign tumors. Interestingly, in a mice melanoma model, the LITIE assay showed the ability to predict immunotherapy response even before drug treatment. Thus, we think the strategy of measuring individual tumor-derived EVs PD-L1 could serve as an alternative way for screening clinical responders suitable for immunotherapy.
- 11 October 2023
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 17 (20) , 20120-20134
Localized Imaging of Programmed Death-Ligand 1 on Individual Tumor-Derived Extracellular Vesicles for Prediction of Immunotherapy Response
Programmed death-ligand 1 (PD-L1) on tumor-derived small extracellular vesicles (EVs) is a biomarker for prediction of the immunotherapy response. However, conventional bulk measurement can hardly analyze the expression of PD-L1 on individual tumor-derived EVs. Herein, a method for localized imaging of tumor-derived individual EVs PD-L1 (LITIE) is developed. In this assay, EVs in plasma were directly captured on a biochip. Then the liposome-mediated membrane fusion strategy was used to image miR-21 in EVs to discriminate miR-21-positive EVs from the whole EVs populations. Subsequently, the primer exchange reaction (PER) is applied to generate localized and amplified fluorescent signals for imaging PD-L1 on identified tumor-derived EVs. When applied in clinical sample tests, the LITIE assay could effectively distinguish breast cancer patients from healthy donors or patients with benign tumors. Interestingly, in a mice melanoma model, the LITIE assay showed the ability to predict immunotherapy response even before drug treatment. Thus, we think the strategy of measuring individual tumor-derived EVs PD-L1 could serve as an alternative way for screening clinical responders suitable for immunotherapy.